ImmunityBio Dirección
Dirección controles de criterios 2/4
El CEO de ImmunityBio es Rich Adcock , nombrado en Oct 2020, tiene una permanencia de 5.83 años. compensación anual total es $12.72M, compuesta por 6.5% salario y 93.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.053% de las acciones de la empresa, por valor de $4.33M. La antigüedad media del equipo directivo y de la junta directiva es de 5.1 años y 5.8 años, respectivamente.
Información clave
Rich Adcock
Chief Executive Officer (CEO)
US$12.7m
Compensación total
| Porcentaje del salario del CEO | 6.54% |
| Permanencia del CEO | 5.8yrs |
| Participación del CEO | 0.05% |
| Permanencia media de la dirección | 5.1yrs |
| Promedio de permanencia en la Junta Directiva | 5.8yrs |
Actualizaciones recientes de la dirección
Recent updates
IBRX: FDA Review Timeline For Bladder Cancer Will Drive Future Upside
Analysts have reset their price target on ImmunityBio from $23 to $15. This reflects updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions.ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold
Summary ImmunityBio (IBRX) remains rated Hold as its $8bn+ valuation relies on future clinical and regulatory milestones, not current fundamentals. Anktiva's clinical data in NMIBC and NSCLC is encouraging, but competition is intense and label expansion is critical for long-term upside. Q1 2026 revenues reached $44.2m, but heavy operating losses and cash burn highlight the need for significant revenue ramp or new funding. Key risks include 'key man' dependence on Dr. Soon Shiong, lack of 2026 guidance, and the need for US approvals beyond NMIBC. Read the full article on Seeking Alpha
IBRX: Saudi Rollout And FDA Label Review Will Drive Future Upside
Analysts have raised their ImmunityBio price target from $11.00 to $12.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of the revision. What’s in the News for ImmunityBio ImmunityBio shares recently reached a 3 month high, with investors focused on July catalysts including the commercial rollout of Anktiva in Saudi Arabia and upcoming updates on second quarter sales performance.
IBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion
Analysts have lowered their ImmunityBio price target slightly from $13.50 to $13.00 as they refresh assumptions around discount rates, revenue growth, margins, and future P/E expectations. What’s in the News for ImmunityBio Retail traders are speculating that ImmunityBio stock could shift from the Russell 2000 to the Russell 1000 based on a cutoff around US$5.7b, with some traders expecting potential index fund buying and changes in volatility if inclusion occurs, according to recent Stocktwits sentiment data and after hours trading moves.Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaAnálisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$992m |
| Mar 31 2026 | n/a | n/a | -US$855m |
| Dec 31 2025 | US$13m | US$832k | -US$351m |
| Sep 30 2025 | n/a | n/a | -US$349m |
| Jun 30 2025 | n/a | n/a | -US$367m |
| Mar 31 2025 | n/a | n/a | -US$409m |
| Dec 31 2024 | US$11m | US$802k | -US$414m |
| Sep 30 2024 | n/a | n/a | -US$588m |
| Jun 30 2024 | n/a | n/a | -US$598m |
| Mar 31 2024 | n/a | n/a | -US$601m |
| Dec 31 2023 | US$1m | US$796k | -US$583m |
| Sep 30 2023 | n/a | n/a | -US$458m |
| Jun 30 2023 | n/a | n/a | -US$473m |
| Mar 31 2023 | n/a | n/a | -US$430m |
| Dec 31 2022 | US$4m | US$791k | -US$417m |
| Sep 30 2022 | n/a | n/a | -US$400m |
| Jun 30 2022 | n/a | n/a | -US$376m |
| Mar 31 2022 | n/a | n/a | -US$370m |
| Dec 31 2021 | US$29m | US$765k | -US$347m |
| Sep 30 2021 | n/a | n/a | -US$323m |
| Jun 30 2021 | n/a | n/a | -US$301m |
| Mar 31 2021 | n/a | n/a | -US$264m |
| Dec 31 2020 | US$843k | US$141k | -US$222m |
Compensación vs. Mercado: La compensación total de Rich($USD12.72M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD8.22M).
Compensación vs. Ingresos: La compensación de Rich ha aumentado mientras la empresa no es rentable.
CEO
Rich Adcock (57 yo)
Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 11.8yrs | US$12.29m | 27.5% $ 2.3b | |
| President | 5.8yrs | US$12.72m | 0.053% $ 4.3m | |
| Chief Financial Officer | 7.1yrs | US$4.24m | 0.028% $ 2.3m | |
| Chief Accounting Officer | 4.8yrs | US$745.31k | 0.011% $ 894.3k | |
| Chief Corporate Affairs Officer & Director | 5.4yrs | sin datos | 0.26% $ 21.6m | |
| Chief Technology Officer | 3.6yrs | sin datos | sin datos | |
| Chief Communications Officer & Head of Patient Advocacy | 6.4yrs | sin datos | sin datos | |
| Senior Vice President of Human Resources | 5.1yrs | sin datos | sin datos | |
| Chief Medical Officer of Liquid Tumors & Cell Therapy | 1.5yrs | sin datos | sin datos | |
| Chief Medical Officer | 6yrs | sin datos | sin datos | |
| Chief Science Officer of Cellular | no data | sin datos | sin datos | |
| Senior VP of Product Development & Cell Therapy Program | 2.6yrs | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de IBRX es experimentado (5.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 11.8yrs | US$12.29m | 27.5% $ 2.3b | |
| President | 5.4yrs | US$12.72m | 0.053% $ 4.3m | |
| Chief Corporate Affairs Officer & Director | 19.6yrs | sin datos | 0.26% $ 21.6m | |
| Independent Director | 6yrs | US$477.28k | sin datos | |
| Independent Director | 5.5yrs | US$470.59k | 0.00075% $ 61.4k | |
| Independent Director | less than a year | US$302.74k | sin datos | |
| Independent Director | 11.1yrs | US$513.38k | 0.025% $ 2.1m | |
| Vice Chairman | no data | sin datos | sin datos | |
| Lead Independent Director | 7.2yrs | US$514.19k | 0.012% $ 967.9k | |
| Independent Director | 5.4yrs | US$489.19k | 0% $ 0 |
Junta con experiencia: La junta directiva de IBRX se considera experimentada (5.8 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/19 22:16 |
| Precio de las acciones al final del día | 2026/08/19 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
ImmunityBio, Inc. está cubierta por 7 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |